STAAR Surgical Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Sales: $93.5 million, up 119.6% year-over-year, driven by strong performance in China and double-digit growth in the Americas.

China Sales: $47.4 million, fueled by the launch of EVO+ ICL and continued demand for EVO.

Adjusted EBITDA: $24.4 million, a significant improvement from a loss of $26.3 million in Q1 2025.

Gross Profit Margin: 73.6%, up from 65.8% year-over-year, due to reduced costs and improved manufacturing efficiencies.

Operating Income: $8 million, compared to a loss of $57.4 million in the prior year.

Net Income: $5.2 million ($0.10 per diluted share), compared to a net loss of $54.2 million ($1.10 per diluted share) in Q1 2025.

Cash Position: $163.9 million, with no outstanding debt.

2Strategic Updates and Business Highlights

Product Launches: Successful launch of EVO+ ICL in China, with strong early demand.

Manufacturing: The Swiss facility is scaling up to supply 100% of EVO and EVO+ lenses to China without import tariffs.

ERP System: Progress in rolling out a new Oracle ERP system, expected to enhance operational visibility and efficiency.

Market Position: Continued share gains in the premium lens-based refractive surgery market, particularly in China.

3Forward Guidance and Outlook

Q2 Expectations: Management expressed optimism for Q2 but refrained from providing specific revenue guidance due to macroeconomic uncertainties and geopolitical risks.

Long-term Growth: STAAR remains focused on revenue growth, profitability, and innovation, particularly in lens-based refractive surgery, which is viewed as a significant long-term growth driver.

4Bad News, Challenges, or Points of Concern

Geopolitical Risks: Ongoing geopolitical tensions, particularly in the Middle East and parts of Asia, could impact sales.

Market Conditions: The overall refractive surgery market remains mixed, with some regions experiencing sluggishness in laser vision correction procedures.

Competitive Pressures: New entrants like iBright in China could pose challenges, although management views competition as validation of market potential.

Inventory Management: While inventory levels have normalized, there are concerns about maintaining appropriate levels in light of fluctuating demand.

5Notable Q&A Insights

Guidance Reluctance: Management is cautious about providing guidance, citing the need for stability in the macroeconomic environment before making predictions.

China Market Stability: There is cautious optimism regarding the stability of the refractive market in China, with management noting that the market appears more stable than in previous years.

Distributor Inventory: The company is closely monitoring distributor inventory levels, which are currently aligned with contractual targets.

Pricing Dynamics: Global pricing pressures are evident, with some regions experiencing declines, but the launch of EVO+ is expected to help stabilize pricing in China.

Growth Expectations: Excluding China, STAAR anticipates continued growth across various markets, with a focus on maintaining discipline in capital allocation and resource prioritization. Overall, STAAR Surgical's Q1 2026 results reflect a strong recovery and growth trajectory, driven by strategic product launches and improved operational efficiencies, despite facing external challenges and competitive pressures.